The Latest Breaking News from Prostate Cancer

A doctor has explained why and when you should see your GP

A new focal therapy that uses high focused beams of ultrasound or cryotherapy to target and treat the cancer leaving surrounding organs and tissue unharmed is set to offer a new lifeline

Findings show that prostate cancer deaths could reduce significantly if less men were overweight

Craig Lowndes will spearhead the driver line-up for a Porsche that will promote the Prostate Cancer Foundation of Australia at the Bathurst 12 Hour.

Having a higher BMI and a larger waistline has been linked to a higher risk of death from prostate cancer.

Experts are starting to unpick the link between prostate cancer and weight

SAN DIEGO — In a horseshoe-shaped booth at bustling Manhattan of La Jolla, Steve Lavin used the better part of 3 1/2 hours to explore the people who have influenced his life, being a 32-year-old college basketball coach under the withering spotlight at UCLA, the prostate cancer that reconfigured perspective…

Myovant Sciences Ltd (NYSE:MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion product in advanced prostate cancer long term. But the surprise Myfembree setback in endometriosis has sparked uncertainty and new investor questions for Myovant's 2nd program. Hence, SVB remains on the…

The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE:MYOV) Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer.  This approval was supported by data from the Phase 3 HERO study. In the HERO study, Orgovyx met the primary endpoint and achieved sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48…